ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly making materially false and misleading statements regarding FDA compliance at its third-party manufacturing vendor. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be entitled to compensation. The lead plaintiff deadline is November 2, 2026.